Results 111 to 120 of about 1,374 (169)

Development of RP-HPLC Method for Simultaneous Determination of Triclabendazole and Ivermectin in Pharmaceutical Suspension Dosage Form. [PDF]

J Anal Methods Chem
Rahman TU, Zaman A, Bahadur A, Zeb MA, Liaqat W, Santali EY, Alharthi S, Omar RMK, Alharthy SA, Ali A.   +9 more
europepmc   +1 more source

Spontaneous rupture of a subcapsular hepatic hematoma due to fascioliasis: A rare parasitic complication managed conservatively - Case report. [PDF]

IDCases
Caballero-Alvarado J, Tapia-Beltrán A, Tirado-López P, Lau-Torres V, Zavaleta-Corvera C.   +4 more
europepmc   +1 more source

Initial Magnetic Resonance Imaging Findings in Hepatic Fascioliasis and Serological and Radiological Response After Triclabendazole Treatment. [PDF]

Am J Trop Med Hyg
Won EJ, Kim KW, Chang EJ, Bae S, Jung J, Chong YP, Lee SO, Choi SH, Kim YS, Kim SH, Kim MJ.   +10 more
europepmc   +1 more source

Fasciolosis Reinfection in Japan. [PDF]

Intern Med
Akiyoshi K, Kokubo-Tanaka M, Yamauchi S, Yonezu K, Abe I, Tawara K, Saito S, Kondo H, Fukuda T, Fukui A, Akioka H, Shinohara T, Teshima Y, Yufu K, Shimono N, Mizuno Y, Irie T, Yoshida A, Takahashi N, Maruyama H.   +19 more
europepmc   +1 more source

Characterization of the clinical features, laboratory findings, and outcomes of human fascioliasis in a global network: a retrospective mutlicenter study. [PDF]

Ther Adv Infect Dis
Henao-Martínez AF, Celis-Salinas JC, Casapia-Morales M, Ramirez-García EA, Chastain DB, Hidron A, Franco-Paredes C, Agudelo Higuita NI, Marcos LA.   +8 more
europepmc   +1 more source

Pancreatitis Manifestation and Mimicking Gallstone Symptoms Caused by Fasciola Hepatica: A Case Report. [PDF]

Middle East J Dig Dis
Bigdeli Shamloo Z, Hormati A, Anushiravani A.   +2 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Triclabendazole for the treatment of fascioliasis and paragonimiasis

Expert Opinion on Investigational Drugs, 2005
Fascioliasis and paragonimiasis, which are caused by liver flukes (Fasciola) and lung flukes (Paragonimus), are emerging public health problems. Several hundred millions of people are at risk of the two diseases that cause considerable morbidity and delay socio-economic development.
Jürg Utzinger, Jennifer Keiser, Dirk Engels   +2 more
exaly   +4 more sources

The effect of the microtubule inhibitor tubulozole-C on the tegument of triclabendazole-susceptible and triclabendazole-resistant Fasciola hepatica

Parasitology Research, 2003
The benzimidazole derivative, triclabendazole is the main drug used against Fasciola hepatica, although its precise mode of action remains to be fully determined. Previous studies have suggested that triclabendazole acts as a microtubule inhibitor in the same manner as tubulozole-C.
Mark W Robinson, Alan Trudgett, Hoey Elizabeth M   +2 more
exaly   +4 more sources

Enhancement of triclabendazole action in vivo against a triclabendazole-resistant isolate of Fasciola hepatica by co-treatment with ketoconazole

Veterinary Parasitology, 2011
An in vivo study in the laboratory rat model was carried out to monitor morphological changes in adult Fasciola hepatica over a 4-day period resulting from combination treatment of triclabendazole (TCBZ) and the metabolic inhibitor, ketoconazole (KTZ). Rats were infected with the TCBZ-resistant Oberon isolate of F. hepatica and divided into 3 groups at
G P Brennan, E Hoey, A Trudgett
exaly   +4 more sources